JP2004536072A5 - - Google Patents

Download PDF

Info

Publication number
JP2004536072A5
JP2004536072A5 JP2002592967A JP2002592967A JP2004536072A5 JP 2004536072 A5 JP2004536072 A5 JP 2004536072A5 JP 2002592967 A JP2002592967 A JP 2002592967A JP 2002592967 A JP2002592967 A JP 2002592967A JP 2004536072 A5 JP2004536072 A5 JP 2004536072A5
Authority
JP
Japan
Prior art keywords
antibody
agent
pharmaceutical composition
hngf
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002592967A
Other languages
English (en)
Japanese (ja)
Other versions
JP4567944B2 (ja
JP2004536072A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/015284 external-priority patent/WO2002096458A1/en
Publication of JP2004536072A publication Critical patent/JP2004536072A/ja
Publication of JP2004536072A5 publication Critical patent/JP2004536072A5/ja
Application granted granted Critical
Publication of JP4567944B2 publication Critical patent/JP4567944B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2002592967A 2001-05-30 2002-05-09 種々の疾患の治療のための抗−ngf抗体 Expired - Lifetime JP4567944B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29439201P 2001-05-30 2001-05-30
PCT/US2002/015284 WO2002096458A1 (en) 2001-05-30 2002-05-09 Anti-ngf antibodies for the treatment of various disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009211917A Division JP5761902B2 (ja) 2001-05-30 2009-09-14 種々の疾患の治療のための抗−ngf抗体

Publications (3)

Publication Number Publication Date
JP2004536072A JP2004536072A (ja) 2004-12-02
JP2004536072A5 true JP2004536072A5 (https=) 2005-12-22
JP4567944B2 JP4567944B2 (ja) 2010-10-27

Family

ID=23133215

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2002592967A Expired - Lifetime JP4567944B2 (ja) 2001-05-30 2002-05-09 種々の疾患の治療のための抗−ngf抗体
JP2009211917A Expired - Lifetime JP5761902B2 (ja) 2001-05-30 2009-09-14 種々の疾患の治療のための抗−ngf抗体
JP2013025893A Withdrawn JP2013139453A (ja) 2001-05-30 2013-02-13 種々の疾患の治療のための抗−ngf抗体
JP2014215231A Pending JP2015061840A (ja) 2001-05-30 2014-10-22 種々の疾患の治療のための抗−ngf抗体
JP2016079748A Expired - Lifetime JP6271631B2 (ja) 2001-05-30 2016-04-12 種々の疾患の治療のための抗−ngf抗体

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2009211917A Expired - Lifetime JP5761902B2 (ja) 2001-05-30 2009-09-14 種々の疾患の治療のための抗−ngf抗体
JP2013025893A Withdrawn JP2013139453A (ja) 2001-05-30 2013-02-13 種々の疾患の治療のための抗−ngf抗体
JP2014215231A Pending JP2015061840A (ja) 2001-05-30 2014-10-22 種々の疾患の治療のための抗−ngf抗体
JP2016079748A Expired - Lifetime JP6271631B2 (ja) 2001-05-30 2016-04-12 種々の疾患の治療のための抗−ngf抗体

Country Status (18)

Country Link
US (7) US7727527B2 (https=)
EP (2) EP2340849A1 (https=)
JP (5) JP4567944B2 (https=)
KR (3) KR20100132559A (https=)
CN (2) CN101653604A (https=)
AT (1) ATE522229T1 (https=)
AU (7) AU2002308722B2 (https=)
BR (1) BR0210231A (https=)
CA (2) CA2448956C (https=)
CY (1) CY1112425T1 (https=)
DK (1) DK1401498T3 (https=)
ES (1) ES2371748T3 (https=)
IL (2) IL158921A0 (https=)
MX (1) MXPA03010911A (https=)
NZ (2) NZ529612A (https=)
PT (1) PT1401498E (https=)
WO (1) WO2002096458A1 (https=)
ZA (1) ZA200308999B (https=)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1401498T3 (da) * 2001-05-30 2011-11-21 Genentech Inc Anti-NGF-antistoffer til behandlingen af forskellige sygdomme
US7255860B2 (en) 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
ZA200502612B (en) 2002-10-08 2007-07-25 Rinat Neuroscience Corp Methods for treating post-surgical pain by administering a nerve crowth factor antagonist and compositions containing the same
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
AU2011201157C1 (en) * 2002-12-24 2017-09-07 Rinat Neuroscience Corp. Anti-NGF antibodies and methods using same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
CN101014364B (zh) 2002-12-24 2012-01-18 里纳特神经系统学公司 抗ngf抗体及其使用方法
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
EP2191846A1 (en) * 2003-02-19 2010-06-02 Rinat Neuroscience Corp. Method for treating pain by administering a nerve growth factor antagonist and an NSAID and composition containing the same
CN102408483B (zh) * 2003-07-15 2016-06-08 安姆根有限公司 作为选择性ngf途径抑制剂的人抗ngf中和抗体
KR100894191B1 (ko) 2003-07-15 2009-04-22 암젠 인코포레이티드 선택적인 ngf 경로 저해제로서의 인체 항-ngf 중화 항체 및 이 항체를 포함하는 약학적 조성물
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
JP5301152B2 (ja) * 2004-04-07 2013-09-25 ライナット ニューロサイエンス コーポレイション 神経成長因子アンタゴニストを投与することによって骨癌の疼痛を処置するための方法
ME00226B (me) * 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
WO2006077441A1 (en) * 2005-01-24 2006-07-27 Cambridge Antibody Technology Limited Specific binding members for ngf
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
EP1857146A1 (en) * 2006-05-16 2007-11-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Treatment of respiratory disorders
BRPI0807952A2 (pt) 2007-02-20 2014-06-10 Anaptysbio Inc Sistemas de hipermutação somática
BRPI0815370B8 (pt) 2007-08-10 2021-05-25 Regeneron Pharma anticorpos humanos de alta afinidade contra o fator de crescimento neural humano e seu uso, molécula de ácido nucleico, vetor de expressão, método para produção de um anticorpo anti-ngf humano e composiçao farmacêutica
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
RU2570559C2 (ru) * 2007-12-17 2015-12-10 Пфайзер Лимитед Лечение интерстициального цистита
BRPI0910482A2 (pt) * 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
PE20100092A1 (es) 2008-06-03 2010-03-12 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
BRPI0913366A8 (pt) 2008-06-03 2017-07-11 Abbott Lab Imunoglobulinas de domínio variável duplo e seus usos
NZ603698A (en) * 2008-07-08 2014-03-28 Abbvie Inc Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
PT2350075E (pt) 2008-09-22 2014-06-09 Array Biopharma Inc Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase
AR074052A1 (es) 2008-10-22 2010-12-22 Array Biopharma Inc Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa
EP2424566A4 (en) * 2009-05-01 2013-07-31 Abbvie Inc IMMUNOGLOBULINE WITH DOUBLE VARIABLE DOMAIN AND ITS USE
SG175436A1 (en) 2009-05-04 2011-12-29 Abbott Res Bv Antibodies against nerve growth factor (ngf) with enhanced in vivo stability
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
KR20120060877A (ko) * 2009-09-01 2012-06-12 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
AU2010306677B2 (en) * 2009-10-15 2013-05-23 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
PE20130203A1 (es) 2010-03-17 2013-03-24 Abbott Res Bv Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
NZ604708A (en) 2010-05-20 2015-05-29 Array Biopharma Inc Macrocyclic compounds as trk kinase inhibitors
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
AU2015258217A1 (en) * 2010-08-19 2015-12-03 Zoetis Belgium S.A. Anti-NGF antibodies and their use
US9505829B2 (en) 2010-08-19 2016-11-29 Zoetis Belgium S.A. Anti-NGF antibodies and their use
PE20140229A1 (es) * 2010-08-26 2014-03-27 Abbvie Inc Inmunoglobulinas con dominio variable dual y usos de las mismas
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
JP6190723B2 (ja) * 2010-12-01 2017-08-30 アルダーバイオ ホールディングス エルエルシー 抗ngf組成物およびその使用
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
ITRM20110024A1 (it) * 2011-01-24 2012-07-25 Consiglio Nazionale Ricerche Uso di antagonisti del recettore p75ntr e/o di agonisti del recettore trka per il trattamento delle malattie infiammatorie croniche.
PT2743348T (pt) 2011-08-11 2018-02-23 Astellas Pharma Inc Novo anticorpo anti-ngf humano
US8926978B2 (en) 2011-10-25 2015-01-06 Anaptysbio, Inc. Antibodies directed against nerve growth factor (NGF)
AR089529A1 (es) 2011-12-30 2014-08-27 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
EP2859018B1 (en) 2012-06-06 2021-09-22 Zoetis Services LLC Caninized anti-ngf antibodies and methods thereof
KR20180008921A (ko) 2012-11-01 2018-01-24 애브비 인코포레이티드 항-vegf/dll4 이원 가변 도메인 면역글로불린 및 이의 용도
US9127055B2 (en) 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
CN105324396A (zh) 2013-03-15 2016-02-10 艾伯维公司 针对IL-1β和/或IL-17的双重特异性结合蛋白
RU2678810C2 (ru) 2014-02-02 2019-02-01 Медиммун Лимитед ХИМЕРНЫЙ БЕЛОК, СОСТАВЛЕННЫЙ ИЗ ДОМЕНА АНТАГОНИСТА NGF И ДОМЕНА АНТАГОНИСТА TNFα
HUE061448T2 (hu) 2014-11-16 2023-07-28 Array Biopharma Inc (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-A]pirimidin-3-il) -3-hidroxipirrolidin-1-karboxamid-hidrogénszulfát kristályos formája
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗vegf、pdgf及/或其受體之結合蛋白
CN108697708A (zh) 2015-10-26 2018-10-23 洛克索肿瘤学股份有限公司 Trk抑制剂抗性癌症中的点突变以及与此相关的方法
ES2987474T3 (es) 2016-04-04 2024-11-15 Loxo Oncology Inc Formulaciones líquidas de (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-IL)-pirazolo[1,5-A]pirimidin-3-IL)-3-hidroxipirrolidina-1-carboxamida
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
ES2836222T3 (es) 2016-05-18 2021-06-24 Loxo Oncology Inc Preparación de (S)-N-(5-((R)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US20180357486A1 (en) * 2017-06-07 2018-12-13 Satori Worldwide, Llc System and method for analyzing video frames in a messaging system
JP2021517461A (ja) 2018-03-12 2021-07-26 ゾエティス・サービシーズ・エルエルシー 抗ngf抗体およびその方法
CN108743568B (zh) * 2018-06-05 2021-09-07 桂林医学院附属医院 用于降低气道高反应性的抗ngf抗体缓释微球及制备方法
CN116178541B (zh) * 2020-08-06 2025-09-30 熙源安健医药(北京)有限公司 抗ngf抗体及其抗原结合片段、其制备方法和应用
BR112023004840A2 (pt) 2020-09-28 2023-04-18 Medimmune Ltd Compostos e métodos para tratamento de dor
MX2023004020A (es) 2020-10-07 2023-07-07 Zoetis Services Llc Anticuerpos anti-ngf y métodos para su uso.
CN116782884A (zh) * 2021-02-02 2023-09-19 南京纽邦生物科技有限公司 Bhb脂质体及其制备方法
WO2023111157A1 (en) 2021-12-16 2023-06-22 Intervet International B.V. Caninized and felinized antibodies to human ngf
US20230348608A1 (en) 2022-04-27 2023-11-02 Regeneron Pharmaceuticals, Inc. Treatment Of Arthropathy Based Upon Stratification Of Osteoarthritis Polygenic Risk Score
AU2024238259A1 (en) 2023-03-17 2025-08-21 Regeneron Pharmaceuticals, Inc. Proteomic risk score for osteoarthritis (oa)
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease
WO2026054762A1 (en) 2024-09-05 2026-03-12 Regeneron Pharmaceuticals, Inc. Proteomic risk score for adjudicated arthropathy (aa)

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4906476A (en) * 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
JPH06503722A (ja) * 1990-11-30 1994-04-28 アボット・ラボラトリーズ 末端欠失神経成長因子受容体の検出に有用なイムノアッセイおよびモノクローナル抗体
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
JP3714683B2 (ja) * 1992-07-30 2005-11-09 生化学工業株式会社 抗リウマチ剤
ES2153384T3 (es) * 1993-07-30 2001-03-01 Kennedy Inst Of Rheumatology Metodo para tratar la esclerosis multiple.
US5753225A (en) * 1993-12-03 1998-05-19 The Regents Of The University Of California Antibodies that mimic actions of neurotrophins
US5728803A (en) * 1994-06-03 1998-03-17 Genentech, Inc. Pantropic neurotrophic factors
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
IT1306704B1 (it) * 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
US6548062B2 (en) * 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
FR2807660A1 (fr) * 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
US7220840B2 (en) * 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
AU2002213441B2 (en) * 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
DK1401498T3 (da) * 2001-05-30 2011-11-21 Genentech Inc Anti-NGF-antistoffer til behandlingen af forskellige sygdomme
EP1545615A4 (en) * 2002-10-04 2006-03-01 Rinat Neuroscience Corp METHODS OF TREATING CARDIAC ARRHYTHMIA AND PREVENTING DEATH OF CARDIAC ARRHYTHMIA USING NGF ANTAGONISTS
UA80447C2 (en) * 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
EP2191846A1 (en) * 2003-02-19 2010-06-02 Rinat Neuroscience Corp. Method for treating pain by administering a nerve growth factor antagonist and an NSAID and composition containing the same
JP5301152B2 (ja) * 2004-04-07 2013-09-25 ライナット ニューロサイエンス コーポレイション 神経成長因子アンタゴニストを投与することによって骨癌の疼痛を処置するための方法

Similar Documents

Publication Publication Date Title
JP2004536072A5 (https=)
JP2010043089A5 (https=)
JP5674654B2 (ja) プロスタグランジンe2二重可変ドメイン免疫グロブリンおよびその使用
JP5819013B2 (ja) Il−17結合タンパク質
JP6271631B2 (ja) 種々の疾患の治療のための抗−ngf抗体
Hyams et al. Use of infliximab in the treatment of Crohn's disease in children and adolescents
KR101539683B1 (ko) Il-1 결합 단백질
JP6009455B2 (ja) Il−1アルファおよびベータ二重特異的二重可変ドメイン免疫グロブリンおよびその使用
MX2010013239A (es) Inmunoglobulinas de dominio variable doble y usos de las mismas.
HU211626A9 (en) Recombinant antibodies
JP2016198102A (ja) 二重可変ドメイン免疫グロブリンおよびその使用
JP2012525155A (ja) 二重可変ドメイン免疫グロブリンおよびこの使用
JP2012510821A (ja) 二重可変ドメイン免疫グロブリンおよびその使用
JP2014500712A (ja) 二重可変ドメイン免疫グロブリンおよびその使用
JP2013535187A (ja) 二重可変ドメイン免疫グロブリンおよびその使用
JP2013539352A5 (https=)
JP2010510323A5 (https=)
RU2006113701A (ru) Лечение респираторных заболеваний антителами против рецептора il-2
JP7093940B2 (ja) 全身性強皮症治療用医薬組成物
JPWO2021170020A5 (https=)
JPWO2022204267A5 (https=)
TW202114734A (zh) Il-17拮抗劑治療自身免疫疾病的方法
JP2002521491A (ja) 関節リウマチまたは皮膚疾患の処置に使用するためのcd25結合分子
Belachew Clinical Application of Therapeutic Bispecific Antibodies
CN121889423A (zh) 使用抗gfral抗体治疗恶心和呕吐病症的方法